Progress in protein degradation has accelerated in the past few years, and 2021 saw several breakthroughs. Efforts to target STAT3, however, have proven to be especially challenging.

RAS mutations are the most common subfamily of oncogenes, so finding inhibitors could be extremely valuable to oncology research. However, they also make for particularly difficult targets. Andreas Mantoulidis explains how BI have been attempting to ‘drug the undruggable.’

Digital tools to boost productivity and optimise pharma manufacturing are becoming increasingly prevalent through smart sensors, AI, ML, virtual reality, and cloud computing. Digital transformation is here for Pharma, and it is changing companies' priorities towards digital solutions.  

How does the MSD group find its targets for neuroscience drugs?

Presented by Alex Titterton, Field Applications Engineer, Graphcore

There are innumerable possible compounds in Merck KGaA’s virtual library, so finding drug candidates is only possible with the help of computational methods.